Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron Capsules for CINV Prevention in Tumor Patients
NCT05690802Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Xijing Hospital. Primary endpoint: Any adverse event after treatment at 1 year. Started May 2022; status: recruiting.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05690802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690802.